MAGEA3 and neuroblastoma: At the author's institution, DC vaccine trials are open incorporating decitabine followed by DC/MAGE-A1, MAGE-A3, and NY-ESO-1 vaccine in the treatment of relapsing/refractory neuroblastoma, sarcomas, and brain tumors.